Inflammasome Therapeutics, Inc.

Biotechnology · NEWTON, MA

BiotechnologySEC Form D

Inflammasome Therapeutics, Inc. filed a Form D with the U.S. Securities and Exchange Commission on May 4, 2026, reporting $13,155,645 raised.

Incorporated in Delaware and based in NEWTON, MA, it operates in the Biotechnology sector.

Companies file a Form D within 15 days of the first sale of securities in a private offering under Regulation D — an early, public signal that Inflammasome Therapeutics, Inc. has raised capital from private investors.

Browse more recently funded companies in Biotechnology.

Executives & Directors

  • Jayakrishna AmbatiExecutive Officer · Director
  • Balamurali K. AmbatiExecutive Officer · Director
  • Chaniyilparampu N. RamchandDirector
  • Napoleone FerraraDirector
  • Babur B. LateefDirector

Recently funded in Biotechnology

Other companies that recently filed a Form D

$3.2MRaised

Goldenrod Therapeutics, Inc.

BiotechnologyHOUSTON, TX
May 26, 2026View SEC Form D
$10.0MRaised

Human Biotech, Inc.

BiotechnologyCAMBRIDGE, MA
May 22, 2026View SEC Form D
$1.0MRaised

Optimeos Life Sciences, Inc.

BiotechnologyPRINCETON, NJ
May 22, 2026View SEC Form D
$2.5MRaised

BioStem Technologies, Inc.

BiotechnologyPOMPANO BEACH, FL
May 21, 2026View SEC Form D
$1.6MRaised

Biolexis Therapeutics Inc.

BiotechnologyLEHI, UT
May 20, 2026View SEC Form D
Inflammasome Therapeutics, Inc. raised $13.2M — SEC Form D